Dashboard
Manage Tickers

REGN REGENERON PHARMACEUTICALS, ...

Nasdaq regeneron.com


$ 558.05 $ -6.90 (-1.22 %)    

Monday, 13-Oct-2025 19:18:02 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 601.81 $ 12.51 (2.12 %)
DIA $ 460.92 $ 5.81 (1.28 %)
SPY $ 662.71 $ 10.02 (1.53 %)
TLT $ 90.54 $ -0.05 (-0.06 %)
GLD $ 379.71 $ 8.97 (2.43 %)
$ 557.73
$ 552.00
$ 555.15 x 41
$ 578.00 x 8
$ 541.00 - $ 563.77
$ 475.76 - $ 1,019.99
1,426,513
na
59.11B
$ 0.72
$ 13.26
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2025 06-30-2025 10-Q
2 04-29-2025 03-31-2025 10-Q
3 02-05-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-05-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-06-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-07-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-08-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 02-07-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-07-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 02-08-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 02-09-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-11-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

regenerons-gene-therapy-shows-significant-gains-in-genetic-hearing-loss
Regeneron's Gene Therapy Shows Significant...
10/13/2025 17:24:21

Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some part...

citigroup-maintains-buy-on-regeneron-pharmaceuticals-raises-price-target-to-660
Citigroup Maintains Buy on Regeneron Pharm...
10/13/2025 15:57:14

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target fro...

reported-sunday-regenerons-db-oto-gene-therapy-yields-sustained-hearing-restoration-and-speech-perception-gains-in-otof-related-hearing-loss
Reported Sunday, Regeneron's DB-OTO Gene T...
10/13/2025 06:39:46

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal ...

forecasting-the-future-9-analyst-projections-for-regeneron-pharmaceuticals
Forecasting The Future: 9 Analyst Projecti...
10/10/2025 18:01:09

morgan-stanley-maintains-overweight-on-regeneron-pharmaceuticals-lowers-price-target-to-756
Morgan Stanley Maintains Overweight on Reg...
10/10/2025 17:24:28

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the p...

regenerons-libtayo-gains-fda-approval-to-reduce-recurrence-risk-in-skin-cancer-patients
Regeneron's Libtayo Gains FDA Approval To ...
10/09/2025 17:59:58

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, b...

regeneron-pharma-says-fda-approves-pd-1-inhibitor-libtayo-as-adjuvant-treatment-for-adult-patients-with-cscc-at-high-risk-of-recurrence-after-surgery-and-radiation
Regeneron Pharma Says FDA Approves PD-1 In...
10/08/2025 18:33:42

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by...

a-look-into-regeneron-pharmaceuticals-incs-price-over-earnings
A Look Into Regeneron Pharmaceuticals Inc'...
10/03/2025 14:02:05

health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday
Health Care Stocks Rally, Nike Beats The S...
10/01/2025 16:56:36

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

nvidia-amphenol-lockheed-martin-and-a-health-care-stock-on-cnbcs-final-trades
Nvidia, Amphenol, Lockheed Martin And A He...
10/01/2025 14:10:09

Nvidia surges past 52-week high, surpasses $4.5 trillion market cap as tech companies invest in AI. Regeneron and Amphenol name...

acuity-lithium-americas-rezolve-ai-aes-and-other-big-stocks-moving-higher-on-wednesday
Acuity, Lithium Americas, Rezolve AI, AES ...
10/01/2025 13:57:33

Core News & Articles
CNBC Halftime Report Final Trades: NVIDIA,...
09/30/2025 17:01:42

Core News & Articles
Live On CNBC, Amy Raskin Announces Bought ...
09/30/2025 16:47:11

fda-expands-use-of-regenerons-evkeeza-to-infants-with-rare-cholesterol-disorder
FDA Expands Use Of Regeneron's Evkeeza To ...
09/26/2025 14:46:53

The U.S.

the-fda-approves-regeneron-pharmaceuticals-evkeeza-evinacumab-dgnb-as-an-adjunct-to-diet-and-exercise-and-other-lipid-lowering-therapies-for-children-from-age-1-to-less-than-5-years-old-with-homozygous-familial-hypercholesterolemia
The FDA Approves Regeneron Pharmaceuticals...
09/26/2025 11:03:07

FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH)HoFH is an ...

eli-lilly-ends-bimagrumab-obesity-study-weeks-after-launch
Eli Lilly Ends Bimagrumab Obesity Study We...
09/25/2025 15:23:56

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients w...

what-does-the-market-think-about-regeneron-pharmaceuticals
What Does the Market Think About Regeneron...
09/24/2025 14:00:48

wall-street-pauses-for-a-breather-small-caps-soar-whats-moving-markets-tuesday
Wall Street Pauses For A Breather, Small C...
09/23/2025 17:31:28

Wall Street paused on Tuesday after three straight sessions of strong gains that pushed major large-cap indices to fresh records.

scholar-rocks-spinal-muscular-atrophy-drug-faces-fda-delay-over-catalent-indiana-inspection
Scholar Rock's Spinal Muscular Atrophy Dru...
09/23/2025 15:32:30

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germ...

fda-delays-key-sanofi-multiple-sclerosis-drug-decision
FDA Delays Key Sanofi Multiple Sclerosis D...
09/22/2025 16:07:06

Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION